Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2018

View Archived Issues

New phase I/II trial investigates nivolumab with PD-L1/IDO peptide vaccine in metastatic melanoma

Phase II trial explores efficacy of TAA-specific CTLs in breast cancer

Altimmune initiates phase I study of NasoShield

GLWL Research recruiting patients with Prader-Willi syndrome for phase II trial of GLWL-01

Pioglitazone shows inadequate effect in delaying onset of MCI due to AD

Phase II clinical data presented for palbociclib in esophageal/gastric cancer

Summit Therapeutics presents 24-week interim analysis results from PhaseOut DMD study of ezutromid

New oncology company Partner Therapeutics launches

MindImmune signs peripheral immune cells research agreement with Pfizer

First patient treated in phase II study of Novan's SB-206 for molluscum contagiosum

Neurolixis receives funding to complete preclinical research for NLX-112 for dyskinesia

Biogen agrees to acquire Karyopharm's oral SINE compound KPT-350

FDA approves Synergy Pharmaceuticals' Trulance for IBS-C

EMA accepts patisiran MAA for hereditary ATTR amyloidosis

AstraZeneca announces topline results from KRONOS trial of PT-010 in COPD

New phase II trial of cabiralizumab in pancreatic cancer triggers milestone payment to Five Prime

Novartis reviews regulatory and pipeline highlights of fourth quarter 2017

Anti-VEGFR-2 ramucirumab shows promising activity in patients with GNEC

Exelixis details phase III results for cabozantinib in hepatocellular carcinoma

Synthon's anti-HER2 ADC awarded FDA fast track status

Boehringer Ingelheim identifies novel cytochrome P450 11B2 inhibtors

New TGF-beta receptor type-1 inhibitors patented by Hanmi

The University of California, Oakland divulges novel anticancer compounds

Novel HIV maturation inhibitors described by ViiV Healthcare

Atea Pharmaceuticals patents new antiviral nucleotide derivatives

SUSD2 shown as predictor of recurrence after gastric cancer resection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...